Chifotides Helen T, Masarova Lucia, Alfayez Mansour, Daver Naval, Alvarado Yesid, Jabbour Elias, Konopleva Marina, Kantarjian Hagop M, Patel Keyur P, DiNardo Courtney D, Verstovsek Srdan
Department of Leukemia and.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Blood Adv. 2020 Nov 10;4(21):5336-5342. doi: 10.1182/bloodadvances.2020001528.
IDH1/2-inhibitor–based combinations conferred significant clinical responses in patients with -mutated post–MPN AML. Complete remission was achieved in 3/7 patients (1 attaining MRD–) with new -mutated post–MPN AML treated with IDH1/2-i combinations.
基于异柠檬酸脱氢酶1/2（IDH1/2）抑制剂的联合治疗方案在伴有IDH1/2突变的骨髓增殖性肿瘤（MPN）后继发性急性髓系白血病（AML）患者中产生了显著的临床反应。在7例接受IDH1/2抑制剂联合治疗的伴有新发生IDH1/2突变的MPN后继发性AML患者中，有3例（1例达到微小残留病阴性）实现了完全缓解。
Zotero 插件